elveInsight’s, “Advanced Recurrent Ovarian Cancer Pipeline Insight 2024” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Advanced Recurrent Ovarian Cancer pipeline landscape. It covers the Advanced Recurrent Ovarian Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Advanced Recurrent Ovarian Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Advanced Recurrent Ovarian Cancer Research. Learn more about our innovative pipeline today! @ Advanced Recurrent Ovarian Cancer Pipeline Outlook
Key Takeaways from the Advanced Recurrent Ovarian Cancer Pipeline Report
June 2024:- Valerio Therapeutics– This is a phase 1/2 open-label, multicenter, basket study to determine the safety, anti-tumor activity, tolerability, and PK/PD of VIO-01 alone or in combination with other anti-cancer therapies in select participants with advanced HRRm or HRD+ solid tumors (i.e. BRCA1/2 mutated breast cancer, HRR mutated prostate cancer) or HRRm/HRD+/HRP (phase 1 only) recurrent ovarian cancer.
June 2024:- A2 Biotherapeutics Inc.- A Seamless Phase 1/2 Study to Evaluate the Safety and Efficacy of A2B694, an Autologous Logic-gated Tmod™ CAR T, in Heterozygous HLA-A*02 Adults With Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
DelveInsight’s Advanced Recurrent Ovarian Cancer pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Advanced Recurrent Ovarian Cancer treatment.
The leading Advanced Recurrent Ovarian Cancer Companies such as IMV, Elucida Oncology, Klus Pharma, Chia Tai Tianqing Pharmaceutical Group, Sumitomo Pharma Oncology, Precigen Inc., Glycotope GmbH, and others.
Promising Advanced Recurrent Ovarian Cancer Therapies such as VIO-01, ELU001, MK-3475 (pembrolizumab), Cyclophosphamide, Pembrolizumab, Ipilimumab, A2B694, JPI-547, Fludarabine, and others.
Stay informed about the cutting-edge advancements in Advanced Recurrent Ovarian Cancer Treatments. Download for updates and be a part of the revolution in cancer care @ Advanced Recurrent Ovarian Cancer Clinical Trials Assessment
Advanced Recurrent Ovarian Cancer Emerging Drugs Profile
Maveropepimut S: IMV
Maveropepimut-S (DPX-Survivac) combines the advantages of the DPX platform and the cancer antigen survivin, is the lead candidate of IMV’s new class of immunotherapies that generates cancer-targeted T cells in vivo. The protein survivin is found in more than 15 types of solid tumor and hematologic cancers. It has been recognized as a promising tumor-associated target because it is overexpressed in a high percentage of tumor types. It is believed Maveropepimut-S’ ability to deliver a sustained flow of T cells that target survivin expressed on cancer cells can lead to more clinically effective anti-tumor therapies. Maveropepimut-S has demonstrated a robust and sustained, antigen-specific immune response with infiltration of targeted T cells into tumors post-treatment which is correlated with prolonged duration of clinical benefits up to more than two years. Maveropepimut-S showed a well-tolerated safety profile with no immune-related, serious systemic adverse events reported. Majority of adverse events being grade 1 and 2 injection site reactions. Compared to traditional immuno-oncology therapies, which require intravenous infusions and safety monitoring, Maveropepimut-S provides lesser burden on patients’ quality of life.
ELU 001: Elucida Oncology
ELU001 is a novel, first-in-class, new molecular entity described as a C’Dot Drug Conjugate (CDC). ELU001 consists of ~12 folic acid targeting moieties and ~22 exatecan topoisomerase-1 inhibitor payloads on Cathepsin-B cleavable linkers covalently bound to the surface of each silicon core/polyethylene glycol C’Dot nanoparticle. CDCs are small in size, have a greater ability to penetrate into and through tumors as compared to ADCs, and are rapidly eliminated by the kidneys. The rapid systemic elimination is expected to lead to less toxicity than is observed with targeting platforms like ADCs that have a longer half-life in circulation. ELU001’s high avidity is believed to promote internalization into FRα overexpressing cancer cells, selectively delivering its payload. Currently, the drug is in Phase I/II stage of Clinical trial evaluation for the treatment of Advanced Recurrent Ovarian Cancer.
A166: Klus Pharma
A166 is a third-generation antibody-drug conjugate (ADC) that incorporates an anti-HER2 antibody conjugated to highly potent auristatin-based payload, via site-specific conjugation and cleavable Val-Cit linker. Currently, the drug is in Phase I/II stage of Clinical trial evaluation for the treatment of Advanced Recurrent Ovarian Cancer.
Learn more about Advanced Recurrent Ovarian Cancer Drugs opportunities in our groundbreaking Advanced Recurrent Ovarian Cancer Research and development projects @ Advanced Recurrent Ovarian Cancer Unmet Needs
Advanced Recurrent Ovarian Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
Intra-articular
Intraocular
Intrathecal
Intravenous
Ophthalmic
Oral
Parenteral
Subcutaneous
Topical
Transdermal
Advanced Recurrent Ovarian Cancer Products have been categorized under various Molecule types such as
Oligonucleotide
Peptide
Small molecule
Discover the latest advancements in Advanced Recurrent Ovarian Cancer Treatment by visiting our website. Stay informed about how we’re transforming the future of Oncology @ Advanced Recurrent Ovarian Cancer Market Drivers and Barriers, and Future Perspectives
Advanced Recurrent Ovarian Cancer Companies and Drugs
TCR2 Therapeutics: Fludarabine
Onconic Therapeutics Inc.: JPI-547
A2 Biotherapeutics Inc.: A2B694
ImmunoVaccine Technologies, Inc. (IMV Inc.): Cyclophosphamide/Pembrolizumab
Valerio Therapeutics: VIO-01
Scope of the Advanced Recurrent Ovarian Cancer Pipeline Report
Coverage- Global
Advanced Recurrent Ovarian Cancer Companies- IMV, Elucida Oncology, Klus Pharma, Chia Tai Tianqing Pharmaceutical Group, Sumitomo Pharma Oncology, Precigen Inc., Glycotope GmbH, and others.
Advanced Recurrent Ovarian Cancer Therapies- VIO-01, ELU001, MK-3475 (pembrolizumab), Cyclophosphamide, Pembrolizumab, Ipilimumab, A2B694, JPI-547, Fludarabine, and others.
Advanced Recurrent Ovarian Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Advanced Recurrent Ovarian Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Advanced Recurrent Ovarian Cancer Pipeline on our website @ Advanced Recurrent Ovarian Cancer Drugs and Companies
Table of Content
Introduction
Executive Summary
Advanced Recurrent Ovarian Cancer: Overview
Pipeline Therapeutics
Therapeutic Assessment
Advanced Recurrent Ovarian Cancer– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Drug name: Company Name
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Maveropepimut S: IMV
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Drug name: Company Name
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company Name
Drug profiles in the detailed report…..
Inactive Products
Advanced Recurrent Ovarian Cancer Key Companies
Advanced Recurrent Ovarian Cancer Key Products
Advanced Recurrent Ovarian Cancer- Unmet Needs
Advanced Recurrent Ovarian Cancer- Market Drivers and Barriers
Advanced Recurrent Ovarian Cancer- Future Perspectives and Conclusion
Advanced Recurrent Ovarian Cancer Analyst Views
Advanced Recurrent Ovarian Cancer Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services
